Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer

Xconomy Boston — 

Seres Therapeutics (NASDAQ: MCRB) has appointed Lisa von Moltke to serve as its executive vice president and chief medical officer. She is joining the Cambridge, MA-based microbiome drug developer from Alkermes (NASDAQ: ALKS), where she was senior vice president and head of clinical development. Her experience also includes positions at Sanofi (NYSE: SNY) and Takeda Pharmaceutical (NYSE: TAK). The most advanced Seres program, SER-109, is in Phase 3 testing as a treatment for recurrent Clostridium difficile infection.